Agios Pharmaceuticals

Agios is focused on developing therapies for rare hemolytic anemias, including thalassemia and sickle cell disease. Our research engine is advancing multiple novel, investigational therapies in preclinical development. Our rare disease therapy was approved by the FDA for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.